Summary
Medtronic plc reported solid revenue growth for the first quarter of fiscal year 2024, with net sales increasing by 5% year-over-year to $7.7 billion. This growth was primarily driven by strong performance across its Cardiovascular and Neuroscience segments, with notable contributions from key products like Micra, TAVR systems, and Spine & Biologics. Diluted earnings per share (EPS) saw a decrease to $0.59 from $0.70 in the prior year period, impacted by a significant $187 million income tax charge related to an Israeli court decision, among other factors. The company maintained a strong liquidity position with $1.3 billion in cash and cash equivalents. Despite facing ongoing macroeconomic challenges, including inflation and supply chain pressures, Medtronic demonstrated resilience and strategic progress, including a pending acquisition of EOFlow to bolster its Diabetes segment. Key financial highlights include a 5% increase in total net sales to $7.7 billion, with the Cardiovascular segment leading growth at 6% and Neuroscience at 5%. The company also reported a 6% increase in Medical Surgical sales and a 7% increase in Diabetes sales, signaling broad-based demand. Free cash flow remained robust at $521 million, underscoring operational efficiency. However, investors should note the decrease in EPS and the increased effective tax rate primarily due to the aforementioned tax charge, which temporarily impacted profitability. Medtronic continues to invest in innovation and strategically expand its product portfolio.
Financial Highlights
55 data points| Revenue | $7.70B |
| Cost of Revenue | $2.63B |
| Gross Profit | $5.07B |
| SG&A Expenses | $2.61B |
| Operating Income | $1.27B |
| Interest Expense | $148.00M |
| Net Income | $791.00M |
| EPS (Basic) | $0.59 |
| EPS (Diluted) | $0.59 |
| Shares Outstanding (Basic) | 1.33B |
| Shares Outstanding (Diluted) | 1.33B |
Key Highlights
- 1Net sales increased by 5% to $7.7 billion, driven by broad-based growth across segments, particularly Cardiovascular and Neuroscience.
- 2Diluted Earnings Per Share (EPS) decreased to $0.59 from $0.70 in the prior year, significantly impacted by a $187 million income tax charge related to an Israeli court decision.
- 3Cardiovascular segment sales grew 6% to $2.9 billion, led by strong performance in Micra, TAVR systems, and Coronary & Peripheral Vascular products.
- 4Neuroscience segment sales rose 5% to $2.2 billion, supported by growth in Spine & Biologics, Neurosurgery, and ENT.
- 5Free cash flow remained strong at $521 million, indicating healthy operational cash generation.
- 6Medtronic is pursuing the acquisition of EOFlow for approximately $760 million to expand its Diabetes segment offerings.
- 7The company reported a higher effective tax rate of 33.4% compared to 10.7% in the prior year, largely due to the tax charge and other adjustments.